Skip to main content
S&P 5007,637.76+1.14%DOW51,778.04+0.61%NASDAQ26,418.30+1.69%BTC$78,229.00+2.44%ETH$2,512.95+3.19%GOLD$4,417.20+0.40%OIL$95.66-1.61%
Smart Investors Daily
CY

NASDAQ · CYTH

Cyclo Therapeutics, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$0.72

Up+$0.00 (+0.00%)

Updated Sep 18, 2026, 11:06 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
23.59M
P/E ratio
-1.4
Dividend yield
0.00%
52-week range
— – —
Volume
186.81K
Avg. volume
1.86M

Price performance

CYTH price history

1M range · 0 trading sessions · Daily adjusted prices

CYTH does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest CYTH news

The latest Smart Investors Daily articles mentioning CYTH.

Stock researchCompany · Overview

CYTH research

Overview

Company profile and research snapshot.

Company profile

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$0.95
Implied upside
—
Analysts
—
CYTH recent ratings
DateFirmRatingTarget
Aug 27, 2024Maxim GroupHold—
Aug 26, 2024Ascendiant CapitalBuy—
Aug 23, 2024HC Wainwright & Co.Neutral—
Aug 16, 2024HC Wainwright & Co.Buy—
May 31, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Sep 23, 2022

Cyclo Therapeutics, TRACON Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying

The Dow Jones dropped by more than 100 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3 Creative Medical Technology Holdings The Trade: Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) President and CEO Timothy Warbington bought a total of 42,000 shares at an average price of $0.59. To acquire these shares, it cost around $24.82 thousand. What’s Happening: The company’s stock dropped around 82% over the past six months. What Creative Medical Technology Does: Creative Medical Technology Holdings Inc is a biotechnology holding company ...

Benzinga · Nov 17, 2021

The Daily Biotech Pulse: Atea Sinks On Termination Of Roche Contract, Pfizer CFO To Retire, GSK-Vir Bag $1B Contract To Supply COVID Antibody Treatment

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Atea Announces Termination of Strategic Collaboration With Roche Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche Holding AG (PNK:RHHBY) will be terminating, effective Feb. 10. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide. Atea shares were slipping 14.96% to $9.66 in premarket trading. Pfizer Veteran Frank D'Amelio to Retire as CFO, Applies For Authorization Of Oral COVID-19 Pill Pfizer, Inc. (NYSE: PFE) announced Frank D'Amelio will retire from his position as chief financial officer and EVP of Global Supply after a nearly 15-year career with the company. Pfizer said it has initiated an external search for a new CFO and D'Amelio has agreed to stay on board through this process and serve in a consulting role through the transition. The company named Mike McDermott, EVP, Chief Global Supply Officer and said he will join Pfizer's executive leadership team reporting to chairman and chief executive officer, Albert Bourla, effective Jan. 1, 2022. Separately, the company announced it is seeking U.S. Food and Drug Administration's emergency use authorization of its investigational oral antiviral candidate, Paxlovid for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalizations or death. Pfizer shares were up 0.77% at $49.98 in premarket trading. Click ...

Benzinga · Nov 17, 2021

A Peek Into The Markets: US Stock Futures Mixed Ahead Of Earnings, Fed Speakers

Pre-open movers U.S. stock futures traded mixed in early pre-market trade after closing mostly flat in the prior session. Investors are awaiting earnings results from Lowe`s Companies Inc (NYSE: LOW), Target Corporation (NYSE: TGT), Cisco Systems Inc (NASDAQ: CSCO) and Cisco Systems Inc (NASDAQ: NVDA). Data on housing starts and permits for October will be released at 8:30 a.m. ET. Federal Reserve Bank of New York President John Williams is set to speak at 9:10 a.m. ET, while Federal Reserve Bank of Cleveland President Loretta Mester will speak at 11:20 a.m. ET. San Francisco Federal Reserve Bank President Mary Daly and Federal Reserve Governor Christopher Waller will speak at 12:40 p.m. ET. Federal Reserve Bank of Chicago President Charles Evans will speak at 4:05 p.m. ET, while Federal Reserve Bank of Atlanta President Raphael Bostic is set to speak at 4:10 p.m. ET. Futures for the Dow Jones Industrial Average fell 19 points to 36,042.00 while the Standard & Poor’s 500 index futures fell 1 point ...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By